Responding to the Supreme Court's request for its views, see
prior post, the Solicitor General recently
recommended granting certiorari and reversing some of the Federal
Circuit's key holdings in Amgen v. Sandoz (Nos. 15-1039 &
15-1195).
The case involves issues central to the application of the
Biologics Price Competition and Innovation Act of 2009 (BPCIA), the
statutory scheme establishing an abbreviated pathway for regulatory
approval of follow-on biologic products. The Federal Circuit held,
first, that a biosimilar applicant cannot provide the statutory
180-day notice of commercial marketing until after the
biosimilar's approval by the FDA and, second, that a biosimilar
applicant is not required to engage in the so-called "patent
dance" and disclose information—such as its aBLA and
manufacturing information—to the original biologic
manufacturer. More information on the Federal Circuit's
decision can be found here and here. The Supreme Court deferred